Human sialidase 2 (NEU2) is a cytoplasmic sialidase that degrades sialylglycoconjugates, including glycoproteins and gangliosides, via hydrolysis of terminal sialic acids to produce asialo-type molecules. Here, we first report the inhibitory effects of a series of synthetic sialyldendrimers comprising three types [Dumbbell(1)6-S-Neu5Ac 6 , Fan(0) 3-S-Neu5Ac 3 and Ball(0)4-S-NeuAc 4 ] toward recombinant human NEU2 in vitro. Among them, Dumbbell(1)6-SNeu5Ac 6 exhibited the most potent inhibitory activity (concentration causing 50% inhibition (IC 50 ), 0.4 0.5 mM). In addition, NeuSLac and NeuSCel carrying thiosialyltrisaccharide moieties exhibited more potent inhibitory effects than NeuSGal and NeuSGlc carrying thiosialyldisaccharides. Docking models composed of NEU2 and the thiosialyloligosaccharide suggested that the active pocket of NEU2 prefers the second galactose-β (Galβ) to the glucose-β (Glcβ) residue in the trisaccharide structure, there being a hydrogen bond between the 4-hydroxy group of the second Galβ and the side chain of the D46 residue of NEU2. The third Glcβ residues of NeuSLac and NeuSCel were also predicted to be stabilized by hydrogen bonds with the side chains of the R21, R304, D358 and Y359 residues of NEU2. NEU2 mutants (D358A and Y359A) exhibited reduced affinity for NeuSLac carrying thiosialyltrisaccharide moieties, suggesting the significant roles of D358 and Y359 residues in recognition of thiosialyltrisaccharide moieties of NeuSLac bound in the active pocket of NEU2. Thus, the present sialyldendrimers could be utilized not only as a new class of NEU2 inhibitors but also as molecular probes for evaluating the biological functions of NEU2, including the catalytic activity and mechanism as to natural substrates carrying sialyloligosaccharides.
Human sialidase 2 (NEU2) is a cytoplasmic sialidase that degrades sialylglycoconjugates, including glycoproteins and gangliosides, via hydrolysis of terminal sialic acids to produce asialo-type molecules. Here, we first report the inhibitory effects of a series of synthetic sialyldendrimers comprising three types [Dumbbell(1)6-S-Neu5Ac 6 , Fan(0) 3-S-Neu5Ac 3 and Ball(0)4-S-NeuAc 4 ] toward recombinant human NEU2 in vitro. Among them, Dumbbell(1)6-SNeu5Ac 6 exhibited the most potent inhibitory activity (concentration causing 50% inhibition (IC 50 ), 0.4 0.5 mM). In addition, NeuSLac and NeuSCel carrying thiosialyltrisaccharide moieties exhibited more potent inhibitory effects than NeuSGal and NeuSGlc carrying thiosialyldisaccharides. Docking models composed of NEU2 and the thiosialyloligosaccharide suggested that the active pocket of NEU2 prefers the second galactose-β (Galβ) to the glucose-β (Glcβ) residue in the trisaccharide structure, there being a hydrogen bond between the 4-hydroxy group of the second Galβ and the side chain of the D46 residue of NEU2. The third Glcβ residues of NeuSLac and NeuSCel were also predicted to be stabilized by hydrogen bonds with the side chains of the R21, R304, D358 and Y359 residues of NEU2. NEU2 mutants (D358A and Y359A) exhibited reduced affinity for NeuSLac carrying thiosialyltrisaccharide moieties, suggesting the significant roles of D358 and Y359 residues in recognition of thiosialyltrisaccharide moieties of NeuSLac bound in the active Introduction Sialidases, also known as neuraminidases (NAs) or exo-α-sialidases, hydrolyze the nonreducing terminal sialic acid linkages in sialylglycoconjugates, and are involved in the regulation of many biological processes including cell proliferation, differentiation and migration, signal transduction, cell-cell interactions, antigen masking and infection by pathogens (Cabezas 1991; Saito and Yu 1995; Achyuthan and Achyuthan 2001; Monti et al. 2010; Miyagi and Yamaguchi 2012) . Human sialidases (NEUs) have been classified as lysosomal NEU1, cytosolic NEU2, plasma membrane NEU3 and mitochondrial or lysosomal NEU4 on the basis of their subcellular distributions, pH optima and substrate specificities (Saito and Yu 1995; Comelli et al. 2003; Monti et al. 2004 ). However, the X-ray crystal structure of only NEU2 ( protein data bank (PDB): 1VCU) among them has been elucidated (Chavas et al. 2005) , and homology modeling for NEU1, NEU3 and NEU4 has been performed based on the amino acid sequence identities between NEU2 and NEU1 (26.6%), NEU3 (38.1%) and NEU4 (35.8%), respectively, to predict the structures of their active pockets (Magesh et al. 2006) .
Sialidase inhibitors have been developed on the basis of the structure-based designs of substrate and catalytic transition state analogues for the active pockets of sialidases of viral, bacterial and mammalian origin to elucidate their biological functions and to produce therapeutics for several diseases, including influenza viral infectious diseases (Miyagi et al. 1993; Wang et al. 2000; Itzstein 2007; Itzstein and Thomson 2009; Magesh et al. 2009 ). However, some influenza viral sialidases inhibitors have been reported to have side effects in patients due to putative inhibition of human NEUs (Hata et al. 2008) . Recently, Chavas et al., (2010) found that several viral sialidases inhibitors, including zanamivir and peramivir, interact with human cytosolic sialidase NEU2 and inhibit its activity, but not oseltamivir, a widely used clinically effective antiinfluenza drug. On the other hand, the contradictory result was previously reported: the potential linkage between the neuropsychiatric side effects of oseltamivir and the symptoms of human sialidase-related disorders was due to a specific interaction between oseltamivir carboxylate, the active form of oseltamivir, and human cytosolic NEU2 resulting in reduced sialidase activity (Li et al. 2007 ). Sialyldendrimers containing terminal thiosialic acid derivatives have also been demonstrated to exhibit potent inhibitory activity toward NAs derived from influenza viral strains (H1N1 and H3N2) (Oka et al. 2009; Sakamoto et al. 2009 ). Therefore, it is possible that sialyldendrimers exhibiting inhibitory activity against influenza NAs could exhibit similar inhibitory activity toward human NEUs. In this study, we first demonstrated the inhibitory effects of sialyldendrimers containing terminal thiosialoside in vitro toward recombinant human NEU2 produced with an Escherichia coli gene expression system. The relationship between the inhibitory potency and structural specificity of terminal sialyloligosaccharides is also discussed.
Results

Inhibitory effects of sialyldendrimers toward recombinant human NEU2
We first examined the inhibitory effects of sialyldendrimers toward recombinant NEU2 activity in vitro with an artificial substrate, 4-methylumbelliferyl-N-acetyl-α-D-acetylneuraminic acid (4-MU-NANA). The structures of the sialyldendrimers used in this study are summarized in Table I . Sialyldendrimers comprise three different types [Dumbbell(1)6-S-Neu5Ac 6 , Fan (0)3-S-Neu5Ac 3 and Ball(0)4-S-NeuAc 4 ] based on their core carbosilane structures in combination with four different terminal thiosialyloligosaccharide residues, including NeuSLac and NeuSCel carrying trisaccharide moieties (Neu5AcSα2 → 6Galβ1 → 4Glc and Neu5AcSα2 → 6Glcβ1 → 4Glc, respectively) as well as NeuSGal and NeuSGlc carrying disaccharides (Neu5AcSα2 → 6Gal and Neu5AcSα2 → 6Glc, respectively). Figure 1 shows the dose-dependent inhibition of NEU2 activity by the sialyldendrimers. The concentration causing 50% inhibition (IC 50 ) values, the concentrations of inhibitors necessary to inhibit 50% of the enzymatic activity, are summarized in Table II . On the other hand, the monomeric sialyloligosaccharides themselves had little inhibitory effect toward NEU2 (data not shown). The inhibitory potencies based on the core structures of the sialyldendrimers were Dumbbell(1)6-S-Neu5Ac 6 > Fan(0)3-S-Neu5Ac 3 = Ball(0)4-S-NeuAc 4 ( Figure 1A-C) . Among them, Dumbbell(1)6-S-Neu5Ac 6 , containing six terminal thiosialoside residues per molecule, showed the highest inhibitory activities (IC 50 , 0.507 mM for NeuSCel and 0.426 mM for NeuSLac) compared with those of the other core structures ( Figure 1 and Table II ). In addition, NeuSLac (IC 50 , 0.426 mM) and NeuSCel (IC 50 , 0.507 mM) were more potent than NeuSGal (IC 50 , 0.823 mM) and NeuSGlc (IC 50 , 1.68 mM) of Dumbbell(1)6-S-Neu5Ac 6 sialyldendrimers. Therefore, the strongest inhibitor as to recombinant human NEU2 was Dumbbell(1)6-S-Neu5Ac 6 with NeuSLac trisaccharides.
We next examined the modes of inhibition of sialyldendrimers to elucidate the inhibition mechanism (Figure 2 ). The 
modes of inhibition of both Dumbbell(1)6-SLac ( Figure 2A ) and Dumbbell(1)6-SCel ( Figure 2B ) were found to be mixed competitive and uncompetitive. The uncompetitive inhibition constant (K iu ) values were 0.31 mM for Dumbbell(1)6-SLac and 0.46 mM for Dumbbell(1)6-SCel, respectively, while the competitive inhibition constant (K ic ) values were 0.12 and 0.17 mM, respectively, although these values for Dumbbell(1) 6-SLac were relatively lower than those for Dumbbell(1) 6-SCel. In contrast, Dumbbell(1)6-SGal containing terminal thiosialyldisaccharides (K i , 0.21 mM) showed a competitive mode of inhibition ( Figure 2C ). From these results, it was assumed that the terminal trisaccharides of sialyldendrimers might interact with sites other than the active pocket of human NEU2, while the thiosialyldisaccharide moieties could bind only to the active pocket located in a relatively deeper region.
Molecular docking of thiosialyloligosaccharides of sialyldendrimers to human NEU2
In order to determine the differences in human NEU2 inhibition by the thiosialyloligosaccharide moieties of dendrimers, docking models as to the active pocket of human NEU2 were constructed on the basis of the NEU2/DANA complex X-ray structure (PDB code: 1VCU). The conditions under which an almost unique configuration with the least steric conflict and proper hydrogen bonds should be formed between oligosaccharide structures and amino acid residues located around the active pocket were also screened, as described under "Materials and methods". As shown in Figure 3A , the thiosialyltrisaccharide structure (Neu5AcSα2-6Galβ1-4Glc) of NeuSLac could be docked to the active pocket without steric hindrance. The thiosialyl residue of NeuSLac could be adopted in a deeper cleft while the lactose (Galβ1-4Glc) was predicted to be located in the surface region around the active pocket ( Figure 3B ). The configuration of the thiosialyl group could also be the same as that of DANA. The spacer-arm portion of a dendrimer was considered to have little influence on the interaction with an NEU2 molecule or inhibition efficacy ( Figure 3C ). As shown in Figure 3D and E, association between the second Galβ residue and the side chain of D46 was predicted. In contrast, association between the second Glcβ residue and D46 should be difficult because of the different configuration of the 4-hydroxy group (4-OH) of the Glcβ residue in NeuSCel (data not shown). As also shown in Figure 3D and E, the third Glcβ residue of NeuSLac was predicted to associate with the side chains of R21, R304, D358 and Y359 via hydrogen bonds. The interactions between the third Glcβ residue of NeuSLac and the side chains of R21, R304, D358 and Y359 of NEU2 may be responsible for the relatively greater potent inhibitory activity of NeuSLac than that of NeuSGal.
Validation of docking of thiosialyloligosaccharides of sialyldendrimers to NEU2 by site-directed mutagenesis of NEU2 In order to confirm the contributions of the D358 and Y359 residues of NEU2 to the interaction predicted by docking models, recombinant NEU2 mutants with the D358A and Y359A substitutions were produced with an E. coli (Origami B strain) gene expression system based on site-directed mutagenesis causing single as well as double D358A and Y359A substitutions. The NEU2 mutant with the D358A (mutant D358A) substitution exhibited 50% of the activity toward 4-MU-NANA of the wild-type enzyme. The Y359A mutant retained almost the same activity as that of the wild-type protein.
The double mutant (D358A/Y359A) had completely lost the catalytic activity toward 4-MU-NANA ( Figure 4A ). The monomeric forms of NEU2 mutants with single substitutions (D358A and Y359A) were used to examine the inhibitory effects of sialyldendrimer Dumbbell(1)6-S-Neu5Ac 6 including NeuSGal with disaccharide moieties and NeuSLac with trisaccharide ones toward the activities of NEU2 mutants. Little effect of Dumbbell(1)6-SGal was observed toward both single mutants (D358A and Y359A). The IC 50 values were 0.813 and 0.822 mM, respectively, which were similar to that of the wild-type NEU2 (IC 50 , 0.823 mM) ( Figure 4B ). On the other hand, a marked decrease in the inhibitory potency of Dumbbell(1)6-SLac was observed for the activities of both single mutants (D358A and Y359A) ( Figure 4C ). The IC 50 values of Dumbbell(1)6-SLac were 6.51 and 5.52 mM for the D358A and Y359A mutants, respectively, which were 15.3 and 12.9-fold greater than that of the wild-type NEU2 (IC 50 , 0.426 mM). We also confirmed that the modes of inhibition of Dumbbell(1)6-SLac for single mutants (D358A and Y359A) were mixed competitive and uncompetitive. The K ic values were 0.82 and 0.67 mM for the D358A and Y359A mutants, respectively, which were 6.8 and 5.6-fold higher compared with that of the wild-type NEU2 (K ic , 0.12 mM; Table III ).
Discussion
Synthetic sialyldendrimers (Table I) composed of carbosilane scaffolds and thiosialoside clusters that are resistant to hydrolysis by sialidases (NAs) were originally developed as a new class of inhibitors for influenza virus infection due to their binding to hemagglutinin (HA) and NA derived from influenza virions (Oka et al. 2009; Sakamoto et al. 2009 ). Sakamoto et al. (2009) demonstrated that Dumbbell(1) 6-S-Neu5Ac 6 of N2-type NA derived from the H3N2 influenza viral strain showed the most potent inhibition at mM order concentration. Fan(0)3-S-Neu5Ac 3 as well as Dumbbell (1)6-S-Neu5Ac 6 also exhibited potent inhibitory activity toward N1-type NA derived from the H1N1 strain.
In the present study, we demonstrated for the first time the inhibitory effects of the same sets of sialyldendrimers toward recombinant human NEU2 in vitro. The inhibitory activities of sialyldendrimers were dependent on the forms of their carbosilane core frames, but, in contrast, the individual moieties of the monomeric sialyloligosaccharide exhibited little inhibitory activity. In particular, Dumbbell(1)6-S-Neu5Ac 6 dendrimers showed the most potent inhibitory effects toward NEU2 activity with an artificial substrate, 4-MU-NANA, one reason being that they have six thiosialyl residues per molecule, although Fan(0)3-S-Neu5Ac 3 showed inhibitory activity similar to that of Ball(0)4-S-Neu5Ac 4 . Oka et al. (2009) also analyzed the structure-activity relationships (SARs) between sialyldendrimers and inhibition of influenza viral infection as well as NA activity, and demonstrated that dumbbell-shaped sialyldendrimers, as supporting carbohydrate epitopes, were the most suitable core scaffolds. As Dumbbell(1)6-S-Neu5Ac 6 and Fan(0)3-S-Neu5Ac 3 sialyldendrimers have hydrophobic regions not covered by thiosialic acid residues, they suggested that these dendrimers might aggregate to form more effective glycoclusters, while Ball(0)4-S-Neu5Ac 4 ones have less hydrophobic regions covered with thiosialic acid residues. The degree of aggregation was considered to be lower than those of the Dumbbell(1)6-S-Neu5Ac 6 and Fan(0) 
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3-S-Neu5Ac 3 ones. Therefore, the shape and structure of the core carbosilane scaffolds were also considered to be important for the inhibitory activities toward NEU2 molecules existing as monomers.
We demonstrated that the inhibitory activities of sialyldendrimers toward human NEU2 could significantly depend on the terminal thiosialyl α(2-6) oligosaccharide structures. The terminal residues of Dumbbell(1)6-SCel and Dumbbell(1) 6-SLac with trisaccharides exhibited stronger inhibitory effects than those of NeuSGlc and NeuSGal with disaccharide residues toward NEU2. We have not performed a similar experiment to elucidate whether thiosialyldendrimers carrying terminal thiosialyl α(2-3) moieties could have inhibitory effects toward NEU2 or not. Oka et al. (2009) demonstrated that the same sialyldendrimers containing terminal thiosialyl α(2-3) lactose moieties exhibit potent inhibitory activities toward influenza NAs. As natural substrates containing terminal sialyl α(2-3) lactose and sialyl α(2-6) lactose moieties can be degraded by human NEU2, sialyldendrimers having terminal thiosialyl α(2-3) residues may be assumed to also exhibit inhibitory activity toward NEU2.
We further elucidated that the modes of inhibition of Dumbbell(1)6-S-Neu5Ac 6 -type NeuSLac, NeuSCel and NeuSGal were different due to the different terminal oligosaccharide structures. NeuSLac and NeuSCel carrying thiosialyltrisaccharide moieties exhibited mixed competitive and uncompetitive modes of inhibition, while NeuSGal carrying a disaccharide moiety was competitive as to the 4-MU-NANA-degrading activity of NEU2. The difference may be due to the presence of sub-sites near the active pocket of NEU2 interacting with the third Glc residue of NeuSLac (Neu5AcSα2-6Galβ1-4Glc) and NeuSCel (Neu5AcSα2 → 6Glcβ1 → 4Glc), respectively, which is absent in NeuSGal. The relatively similar values and degrees of K iu and K ic of both Dumbbell(1)6-S-Neu5Ac 6 -type NeuSLac and NeuSCel also suggested a common mechanism of inhibition as to NEU2 activity.
Our results also suggested a higher affinity of Dumbbell(1) 6-SLac (K ic , 0.12 mM) for human NEU2 in comparison with the reported K i values of peramivir and DANA (0.33 and 0.14 mM, respectively) (Chavas et al. 2010) , although the IC 50 value of DANA (0.069 mM) has been found to be 6-fold lower than that of Dumbbell(1)6-SLac (0.426 mM) (Table II) .
To predict the differences in the mechanism of inhibition of NEU2 by sialyldendrimers, we constructed docking models between them on the basis of the NEU2/DANA complex crystal structure (PDB code: 1VCU) (Chavas et al. 2005) . First, the terminal thiosialyl residues and DANA could take on similar conformations in this model and thus could be merged without steric conflict ( Figure 3A ). In the model of the NEU2/ Fig. 4 . Properties of NEU2 mutants including D358A, Y359A and D358A/ Y359A. (A) The specific activities (µmol/h/mg protein) of the wild-type and NEU2 mutants were measured. The dose-dependent inhibition of the wild-type and NEU2 mutants (D358A and Y359A) was examined using sialyldendrimers, Dumbbell(1)6-S-Neu5Ac 6 , with the disaccharide moieties of NeuSGal (B) and the trisaccharide moieties of NeuSLac (C). NeuSLac (Neu5AcSα2-6Galβ1-4Glc) trisaccharide complex, the 4-OH of the βGal residue was predicted to associate with the oxygen atom of the side chain of D46 of NEU2 via a hydrogen bond. These docking conditions did not cause steric hindrance between NeuSLac and the active pocket of NEU2. In contrast, the corresponding 4-OH of the second βGlc residue in NeuSCel (Neu5AcSα2 → 6Glcβ1 → 4Glc) was predicted not to associate with the oxygen atom of D46 via a hydrogen bond because the configuration of the 4-OH group places it on the opposite side of the second Glc residue in the thiosialyltrisaccharide compared with that of the second Gal residue. The structural difference between the second Gal and Glc residues of terminal thiosialyltrisaccharides could be responsible for the difference in inhibitory activity between NeuSLac (K ic , 0.12 mM) and NeuSCel (K ic , 0.17 mM). Additionally, the importance of the third Glc residues present in NeuSLac and NeuSCel were predicted in this study. The third Glc residue of the NeuSLac (Neu5AcSα2-6Galβ1-4Glc) trisaccharide could interact with the side chains of polar amino acid residues (R21, R304, D358 and Y359) located on the surface of the active pocket of NEU2 (Figure 3) . The residues D46, R21 and R304 were considered to be particularly important for the coordination of thiosialyltrisaccharide moieties (Neu5AcSα2-6Galβ1-4Glc), as previously reported (Chavas et al. 2005; Buschiazzo and Alzari 2008) . The catalytic center of sialidases including NEU2 contains strictly conserved residues R21 and R304 belonging to the arginine triad that binds to the carboxylate group of sialic acids, and an aspartic acid (D46) that acts as the acid/base catalyst in the catalytic reaction. The 2-OH group of the third Glc residue could form a hydrogen bond with the oxygen atom of D358. There is also enough space in the active pocket to bind a lactose (Galβ1-4Glc) moiety. The present inhibition study showed that the inhibitory activities of NeuSGal and NeuSGlc with thiosialyldisaccharide structures were less potent than those of NeuSLac and NeuSCel with thiosialyltrisaccharides. It is suggested that the interactions between the third Glc residue and the side chains of amino acids (R21, R304, D358 and Y359) may increase the ability of NeuSLac (K ic , 0.12 mM) and NeuSCel (K ic , 0.17 mM) to inhibit NEU2 more potently compared with NeuSGal (K i , 0.21 mM), because it has no third Glc residue.
As shown in Figure 3C (indicated by an arrow), the 1-OH group of the third Glc residue is covalently bound to the alkyl portion of the spacer-arm of sialyldendrimers, and could be exposed on the surface of the active pocket of NEU2. In addition to the relatively stronger association between the active pocket and sialyltrisaccharides with the third Glc residue, the alkyl portion of dendrimers could interact with the adjacent hydrophobic residues (indicated by a black oval). On the other hand, the alkyl portion of dendrimers carrying the sialyldisaccharide structure may not be stabilized because of the absence of the third Glc residue and the improper location of the hydrophobic alkyl portion of the spacer-arm. These factors, including the hydrogen bond formation between the third Glc residue of sialyltrisaccharides, the spatial docking conditions as to the active pocket of NEU2 and stabilization of the alkyl portion of the spacer-arm of dendrimers, may explain why the K ic values of NeuSLac and NeuSCel for NEU2 are smaller than those of NeuSGal and NeuSGlc.
In order to prove the significant interaction between the third Glc residue of NeuSLac and the D358/Y359 residues of NEU2 predicted on computational analysis, we evaluated the inhibition potencies of NeuSLac and NeuSGal toward mutant NEU2 activities. Among the single D358A and Y359A and double D358A/Y359A mutants, the single D358A and Y359A mutants retained 50 and 100% of the 4-MU-NANAdegrading activity of the wild-type NEU2, respectively, while the D358A/Y359A double mutant did not show any activity. As we purified the recombinant monomeric D358A and Y359A mutants with 4-MU-NANA-degrading activity, the sensitivities to sialyldendrimers NeuSLac carrying thiosialyltrisaccharides with third Glc residue and NeuSGal carrying thiosialyldisaccharides without the third Glc residue were compared. The remarkable increases in the K ic values of Dumbbell(1)6-SLac but not Dumbbell(1)6-SGal toward the D358A and Y359A mutants suggest that the side chains of the D358 and Y359 residues should contribute to the interaction and stabilization of binding with the third Glc residue. In contrast, the D358 and Y359 residues were demonstrated not to have effects on binding of the thiosialyldisaccharides of NeuSGal to the active pocket of NEU2.
Recently, the interactions between natural as well as artificial substrates and the active pocket of NEU2 have been reported to determine the substrate recognition through homology modeling and site-directed mutagenesis based on the crystal structure of the NEU2/DANA complex (Mozzi et al. 2012) . They found that Q270 of NEU2 is involved in the coordination of the disaccharide α(2-3) sialylgalactose, and K45 and Q112 are involved in the recognition of the Glc moiety of the trisaccharide α(2-3) sialyllactose. They also proved the involvement of the E218 residue in hydrolysis along with D46 by using artificial substrate 4-MU-NANA and natural substrates α(2-3) sialyllactose and GM3 monosialoganglioside. Albohy et al. (2010) examined the roles of residues of NEU3 in recognition of GM3 trisaccharides containing the central Galβ and terminal Glcβ residues. The predicted residues of NEU3 including R48 interact with the central Galβ residue, and R114 and H277 are involved in the interaction with the reducing-end Glc of GM3 trisaccharide. The residues R114 and H277 of NEU3 corresponded in alignment and homology model to the Q112 and Q270 residues of NEU2, as reported by Mozzi et al. (2012) . In their docking study, they found that Q270 could interact with the central Galβ instead of the end Glc. In comparisons, we showed here that the residues D358 and Y359 could be involved in the coordination of NeuSLac by interacting with the Glc moiety of the α(2-6) thiosialyllactose, which were different from those of K45 and Q112 predicted by Mozzi et al. (2012) for interacting with the trisaccharide α(2-3) sialyllactose. The discrepancy may be due to difference in the configuration of trioligosaccharides including α(2-3) sialyllactose as well as GM3 trisaccharide containing terminal α(2-3) sialic acid residue docked into the active pockets of NEU2 and NEU3, and of α(2-6) thiosialyllactosyl group of sialyldendrimers docked into that of NEU2. Different molecular interactions might be predicted according to the different templates used in each docking study.
In conclusion, we have examined the inhibitory potencies of a series of sialyldendrimers as to the enzymatic activity of recombinant human cytosolic sialidase 2 (NEU2) in vitro depending on carbosilane scaffolds and especially on the terminal thiosialyloligosaccharides. We also predicted a relationship between the inhibitory activities (specificity) and the structures of the sialyloligosaccharides by constructing docking models of NEU2/α(2-6) thiosialyloligosaccharide complexes, and validated the prediction through site-directed mutagenesis of NEU2. In our study, we found that novel residues D358 and Y359, which are located on the surface of the active pocket of NEU2, could recognize the reducing terminal Glc residues of α(2-6) thiosialyloligosaccharides. The present new class of synthetic sialyldendrimers can be utilized as tools to analyze the substrate specificities and catalytic mechanisms of sialidases including human NEUs (NEU1 4) and viral NAs.
Materials and methods
Materials and synthetic sialyldendrimers 4-methylumbelliferyl-N-acetyl-α-D-neuraminic acid (4-MU-NANA) was purchased from Nacalai Tesque, Inc. (Kyoto, Japan). A GenomeLab DCIT-Quick start kit, CEQ separation Gel-LPAI and CEQ separation buffer were purchased from Beckman Coulter (North Harbor, CA). A Wizard plus midipreps DNA purification kit, dNTPs and Age1 restriction endonuclease were purchased from Promega (Madison, WI). EcoR1 restriction endonuclease was from BioLabs (Beverly, MA, USA). A Quick gel extraction kit and purification kit were purchased from QIAGEN (Germantown, MA). KOD plus polymerase was from Toyobo (Osaka, Japan). DNA ligation kit ver. 1 (version 1) was purchased from Takara (Otsu, Japan). The series of sialyldendrimers tested in this study was systematically synthesized as described previously (Oka et al. 2009; Sakamoto et al. 2009 ). Briefly, sialylated dendrimers with a thioglycosidic linkage that are resistant to hydrolysis by sialidases were synthesized by means of condensation reaction between a thiosialoside modified at the aglycon terminal end by a thioacetyl group and different types of carbosilane dendrimers having brominated terminal ends under deacetylation conditions, and temporal re-protection was performed for purification. Removal of all protection of the sialyldendrimers was accomplished by transesterification and subsequent saponification to provide the corresponding water-soluble sialyldendrimers in good yields. We selected a series of sialyldendrimers for studying the effects toward recombinant human NEU2 that consisted of Fan(0)3, Ball(0)4 and Dumbbell(1)6, named according to their shapes, generation numbers and numbers of terminal ends.
Site-directed mutagenesis of NEU2 Site-directed mutagenesis of NEU2 was performed to create single-and double-mutated genes encoding mutant proteins comprising D358A, Y359A and D358A/Y359A, respectively, by using appropriate primer sets and the pGEX-2T vector as a template for two-step polymerase chain reaction (PCR). The amplified DNA fragment containing the desired mutation(s) was digested with Age1 and EcoR1, used as an insert, and then ligated into the pGEX-2T vector digested with the same endonucleases. The transformed E. coli (DH5α) cells with ligated DNA was grown in ampicillin-containing lysogeny broth (LB) medium to isolate the expression vectors containing the mutated NEU2 cDNAs. The sequence of the mutated genes was confirmed by base sequencing (CEQ8000 Genetic Analysis Systems, Beckman Coulter, CA), using appropriate primer sets.
Expression and purification of the wild-type and mutant recombinant NEU2 The coding region of NEU2 was subcloned into the pGEX-2T vector (GE Healthcare, Uppsala, Sweden) as described elsewhere (Tringali et al. 2004 ) to produce an expression vector, pGEX-2T-NEU2, encoding the glutathione S-transferase (GST)-human NEU2 fusion protein containing a thrombinrecognition amino acid sequence between the two enzyme open reading frames. E. coli Origami B cells (Takara, Tokyo, Japan) were transformed with the plasmid, pGEX-2T, containing the wild-type and mutant NEU2, and the transformed cells were grown in 4 L of LB-ampicillin medium at 37°C until the optical density became 0.6 before the addition of isopropyl-α-D-thiogalactopyranoside (IPTG). After 40 h growth at 27.5°C in the presence of 0.1 mM IPTG, cells were harvested by centrifugation and suspended in phosphatebuffered saline (PBS). The cells derived from 4 L culture were then lysed in PBS ( pH 7.4) by sonication, and a supernatant was obtained by centrifugation at 5500 rpm for 15 min, during which Triton X-100 was added to a final concentration of 1%. The resultant supernatant (20 mL) containing the GST-NEU2 fusion proteins was applied to a 6 mL GSH-Sepharose (GE Healthcare, Uppsala, Sweden) affinity chromatography column equilibrated with PBS ( pH 7.4) containing 1% Triton X-100. Cleavage of the thrombinrecognition sequence located between the GST and NEU2 in fusion proteins was carried out by adding 100 µL of a thrombin solution comprising 1 IU in PBS and then incubation of the column for 16 h at 22°C. The eluted NEU2 was then applied to a diethylaminoethyl (DEAE) Sepharose ion exchange chromatography column equilibrated with 10 mM sodium phosphate buffer ( pH 8.0) containing 1 M NaCl, and the NEU2 proteins were eluted as the pass-through fraction using an AKTA apparatus (GE Healthcare). The crude cell lysate and fractions obtained during the purification procedures were assayed for NEU2 activity, and the protein concentration of each fraction was also determined according to the method of (Lowry et al. 1951) . The purity of the enzyme fraction was determined by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (Laemmli 1970) and Coomassie brilliant blue (CBB R-350) staining.
Enzyme and inhibition assaying of the wild-type and mutant recombinant NEU2 The wild-type and mutant NEU2 enzyme activities in homogenates of the transformed E. coli cells, the fractions obtained during the purification procedures, and the purified recombinant NEU2 were measured using the synthetic substrate 4-MU-NANA by fluorimetric assaying as previously described with minor variation (Tringali et al. 2004) . Routinely, the reaction mixture (40 μL) was composed of 8 μL of 0.2 M sodium acetate buffer ( pH 6.0), 2 μL of 50 mg/mL bovine serum MM Rahman et al. albumin (BSA), 5 μL of 2 mM 4-MU-NANA, 20 μL of an appropriately diluted inhibitor solution and 5 μL of recombinant NEU2. In the inhibition assay for NEU2, the enzyme activity in this mixture was maintained at 9.5 nmol/30 min/5 μL. After incubation for 30 min at 37°C, 770 μL of glycine-NaOH ( pH 10.7) was added to stop the reaction. The fluorescence of the released 4-methylumbelliferone (4-MU) was measured using a spectrofluorometer (Fluoroskan Ascent Microplate Fluorometer, Finland) at 360 nm (excitation) and 455 nm (emission). The IC 50 of each inhibitor for NEU2 activity was also determined. To evaluate the mode of inhibition by each inhibitor, the concentration of inhibitor versus the reaction rate was plotted, and K i , K ic and K iu values were determined by the method of (Burk and Lineweaver 1930) .
Molecular docking
A docking model was constructed on the basis of the X-ray crystal structure of the human NEU2/DANA complex (PDB code: 1VCU) (Chavas et al. 2005) . The NeuSLac (Neu5AcSα2-6Galβ1-4Glc) structure was constructed with the chemical structural modeling software Marvin (ChemAxon, Budapest, Hungary). The coordinates of the sialyl residues were extracted from sialyl α(2-3) lactose complexed with Trypanosoma cruzi trans-sialidase (PDB ID: 1S0I) (Amaya et al. 2004) . Next, the sialyl residue was modified to a thiosialyl one, and then Galβ1-4Glc was attached to the thiosialyl residue through an α(2-6) linkage. The NeuSLac model was docked into the structure of human NEU2 by superimposing the sialyl residue of NeuSLac onto DANA within NEU2 with Waals (Altif Labs, Inc., Tokyo, Japan). The root mean square deviation value of the sialyl residues of NeuSLac and DANA was 0.266 A. To prevent steric clashing between NeuSLac and NEU2, structural adjustment of rotamers and energy minimization were performed with Swiss-PdbViewer (Guex and Peitsch 1997) . Surface structure constructing was performed with PyMol (http://www.pymol.org).
